PLx Pharma Inc. (PLXP) Reports Q1 EPS Loss of $2.71, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
PLx Pharma Inc. Reports First Quarter 2019 Results
May 10, 2019 6:50 AM EDTHOUSTON, May 10, 2019 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (PLx or the Company), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard delivery system to provide more effective and safer products, Vazalore 325 mg and Vazalore 81 mg (referred to together as Vazalore), announced today certain financial and operational results for the three months ended March 31, 2019.
Highlights of, and certain events subsequent to, the first quarter of 2019 include:
Net loss attributable to common shareholders totaled $23.7 million, or ($2.71) per share, compared to net income of $5.0 million, or $0.57... More